I just ran an article on CancerNews.US this afternoon about some important cancer research news:
Ruxolitinib Shows Continued Progress In Phase 3 Trials Against Rare Blood Cancer, Myelofibrosis.

I understand it is difficult to get excited about a new drug used to treat a cancer you probably have never heard of.  So here is some background info about myelofibrosis, provided by Novartis and Incyte:

 Myelofibrosis (MF) is an uncommon, life-threatening blood cancer characterized by bone marrow failure, enlarged spleen (splenomegaly), debilitating symptoms including fatigue, night sweats and pruritus, poor quality of life, and weight loss, as well as shortened survival. MF is one of the Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) which also includes polycythemia vera and essential thrombocythemia. Of the JAK-associated MPNs, MF carries the greatest risk of a poor prognosis, including transformation to fatal acute myelogenous leukemia, and there are currently no approved treatments for MF in the US. Although allogeneic stem cell transplantation may cure MF, the procedure is associated with significant morbidity and mortality and is usually appropriate only in younger patients.

Sounds pretty awful!  Hope these new meds can help. 
 
Feel good and keep smiling!  Pat

Leave a Reply